EUVIMEDEUVIMED entdecken
Crossref

Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma

Chun-Xiang Huang, Xiang-Ming Lao, Xu-Yan Wang, Yi-Zheng Ren, Yi-Tong Lu, Wei Shi, Ying-Zhe Wang, Cai-Yuan Wu, Li Xu, Min-Shan Chen, Qiang Gao, Lianxin Liu und 2 weitere

Cancer Cell · 2024-12 · 42 (12) · 2082-2097.e10

DOI: 10.1016/j.ccell.2024.10.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2024-12. Verfasst von Chun-Xiang Huang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Province Key Laboratory of Pharmaceutical Functional Genes, MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Su…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, T-Lymphocytes, Cytotoxic, Immunotherapy. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Guangdong Provincial Natural Science Foundation, National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hyperprogressive disease can occur in cancer patients receiving immune checkpoint blockade (ICB) therapy, but whether and how reactive cytotoxic T lymphocytes (CTLs) exert protumorigenic effects in this context remain elusive. Herein, our study reveals that pericancerous macrophages cross-present antigens to CD103+ CTLs in hepatocellular carcinoma (HCC) via the endoplasmic reticulum (ER)-associated degradation machinery-mediated cytosolic pathway. This process leads to the retention of CD103+ CTLs in the pericancerous area, whereby they activate NLRP3 inflammasome in macrophages, promoting hepatoma progression and resistance to immunotherapy. Our single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics analysis of HCC patients shows that despite their tissue-resident effector phenotype, the aggregation of CD103+ CTLs predicts unfavorable clinical outcomes for HCC patients receiving multiple types of treatment. Correspondingly, therapeutic strategies that redistribute CD103+ CTLs can disrupt this pathogenic interplay with macrophages, enhancing the efficacy of ICB treatment against HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsT-Lymphocytes, CytotoxicImmunotherapyMacrophagesIntegrin alpha ChainsHumansMiceAnimalsCross-PrimingAntigens, CDImmune Checkpoint InhibitorsNLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesTumor MicroenvironmentCell Line, TumorMice, Inbred C57BL

Stichwörter der Autor:innen

CD103(+) CTLscross-presentationhepatocellular carcinomaimmune checkpoint blockadepathogenic inflammationpericancerous macrophages

Substanzen

Integrin alpha ChainsAntigens, CDalpha E integrinsImmune Checkpoint InhibitorsNLR Family, Pyrin Domain-Containing 3 ProteinInflammasomesNLRP3 protein, human

Autor:innen und Institutionen

  • Guangdong Province Key Laboratory of Pharmaceutical Functional Genes, MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China.
  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou 510060, China.
  • Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
  • Department of Hepatobiliary Surgery, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
  • Guangdong Province Key Laboratory of Pharmaceutical Functional Genes, MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat-sen University, Guangzhou 510275, China; Innovation Center of th…

Förderung

  • Guangdong Provincial Natural Science Foundation
  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Huang, C. X., Lao, X. M., Wang, X. Y., Ren, Y. Z., Lu, Y. T., Shi, W., Wang, Y. Z., Wu, C. Y., Xu, L., Chen, M. S., Gao, Q., Liu, L., Wei, Y., & Kuang, D. M. (2024). Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. Cancer Cell, 42(12), 2082-2097.e10. https://doi.org/10.1016/j.ccell.2024.10.012

Vancouver

Huang CX, Lao XM, Wang XY, Ren YZ, Lu YT, Shi W, et al. Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. Cancer Cell. 2024;42(12):2082-2097.e10. doi:10.1016/j.ccell.2024.10.012

BibTeX
@article{Huang2024,
  author = {Huang, Chun-Xiang and Lao, Xiang-Ming and Wang, Xu-Yan and Ren, Yi-Zheng and Lu, Yi-Tong and Shi, Wei and Wang, Ying-Zhe and Wu, Cai-Yuan and Xu, Li and Chen, Min-Shan and Gao, Qiang and Liu, Lianxin and Wei, Yuan and Kuang, Dong-Ming},
  title = {Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {12},
  pages = {2082--2097.e10},
  doi = {10.1016/j.ccell.2024.10.012}
}
Kostenlos starten →